Superficial bladder cancer does recur despite bacillus Calmette–Guérin (BCG) instillations—currently the most effective prophylactic therapy. Antifibrinolytic agents seem to enhance the efficacy of ...
Intravesical therapy involving bacillus Calmette–Guérin (BCG) is standard of care for high-grade, noninvasive urothelial carcinoma, with reported cure rates higher than 70%. Systemic infection occurs ...
Radium-223 and atezolizumab in platinum refractory urothelial carcinoma with bone metastases: NCT03208712. Background: BCG unresponsive NMIBC includes patients with persistent high-grade disease or ...
BCG therapy for NMIBC is associated with significant symptoms and side effects, but combining it with chemotherapy reduces these effects. BCG induction with maintenance is less toxic than induction ...
AUA 2017, bladder, urine, cancer, full bladder, illustration, urinary system Early administration of BCG induction following transurethral resection of bladder tumor is safe, and delays do not affect ...
Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...
A 65-year-old man with a history of T1 high-grade bladder cancer with CIS underwent successful transurethral resection of bladder tumor (TURBT), without residual tumor on second resection. Given his ...
Imfinzi addition to BCG therapy significantly improved DFS in high-risk NMIBC patients, with a 32% reduction in DFS events. The study involved 1,018 patients, with three cohorts receiving different ...
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results